Icon

ACTIGALL (nda019594)- (150MG,300MG)

URSODIOL TEVA BRANDED PHARM
150MG,300MG
No No
Expired Expired
None None
None No
Actigall is indicated for patients with radiolucent, noncalcified gall bladder stones < 20 min in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. Actigall is indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss.
13 0 12
Total Other Developers 14
Drugs with Suitability Yes
150MG ** ** - - -
300MG ** ** - - 11
NDA Sales Available Total Generic Sales Available
No 11
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** **** ****** **** ******, *** *********** ***** ***** ******* ******, *********, *** **** (**) *****, ****** ****** (***) ***
****** ******* ** *** ******* *******, ***. *********** **** * *** *, *******, ******* (**) *****, ****** ****** (***) ***
****** ******* ********** ***** *************** ***. *********** **** ******* ***** ****, **********, **** ******** (**) *****, ****** ****** (***) ***
****** ******* ****** ******* ****** ******* ******* *********** ** **/*,******************, ********* *****, ****** *****, *********, ********* ******, ***** (***) ***
****** ***** *** ***-****, ***. *********** *** ***** **., *******, ************ (**) *****, ****** ****** (***) ***
****** ****** ****** ** ****** *************** ******* ******* *********** **** ** ** & **, ******* ******* ******** **** *******-***** *.*. **. **, ***.: ******, ***.: ******, *********, ** ******, ***** (***) ***
****** ****** ******** ********* ************** ******* ******* *********** ***** **. ***/*** *** ****/***/*, **** **, ****** ****, (** *) ******* *****, *********** *****, *********, ** ******, ***** (***) ***
****** ****** ****** **** ******* *** *********** **** **. **, ** & **, ******* ****** ***** *********** *******, ******** ******, **********, ****** ******* ******, ***** (***) ***
****** ****** ****** **** ******* *********** **** **. **, ** & **, ******* ****** ***** *********** *******, ******** ******, **********, ****** ******* ******, ***** (***) ***
****** ***** ************ ***** ************ ******* *********** **** **. *-*/*&* *******, (******* ******** ****) ******, ******* ***** *.*. **. **, ***-******, ****-*********, *********, ******* ******, ***** (***) ***
****** ** ****** ****** **** ******** ********* *** *** *********** ****** ** *** & ***, ******* **** ****, ********* *******, ********-************* ******, *******-*********** ********, *********, ********* ******, ***** (***) ***
****** ********* ****** *** *** ********** ******* *********** ****-*, **. **. ***/*, ***/*, ***/*, **** **. *-*/*, ***** ***, ***** ********** ****, ********* (*******), ********* (******), ************ (********), ************, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.